In particular, the second line anti-TB drug, para-aminosalicylic acid (PAS), specifically blocks growth of M. tb when its active forms inhibit dihydrofolate reductase activity, an essential enzyme in folate metabolism [32,33]. This evidence concerns the gene DHFR and tuberculosis.